PathScan^® Total Chk1 Sandwich ELISA Antibody Pair #7873

CST's PathScan^® Total Chk1 Sandwich ELISA Antibody Pair is offered as an economical alternative to our PathScan^® Total Chk1 Sandwich ELISA Kit #7872. Capture and detection antibodies (100X stocks) and an HRP-conjugated secondary antibody (1000X stock) are supplied. Sufficient reagents are supplied for 4 x 96 well ELISAs. The Chk1 mouse capture antibody is coated onto a 96 well microplate overnight in PBS. After blocking, cell lysates are added, followed by Chk1 detection antibody and anti-rabbit IgG, HRP conjugated antibody. HRP substrate, TMB, is added for color development. The magnitude of the absorbance at 450 nm is proportional to the quantity of total Chk1.

Antibodies in kit are custom formulations specific to kit.

Antibody pairs have been optimized using recommended buffers, reagents, plates and the included protocol. Solutions should be made fresh daily.

For Antibody Pair specificity and sensitivity, please refer to the corresponding PathScan® Sandwich ELISA Kit. Note: This antibody pair detects proteins from the indicated species, as determined through in-house testing, but may also detect homologous proteins from other species.

Chk1 kinase acts downstream of ATM/ATR kinase and plays an important role in DNA damage checkpoint control, embryonic development, and tumor suppression (1). Activation of Chk1 involves phosphorylation at Ser317 and Ser345 by ATM/ATR, followed by autophosphorylation of Ser296. Activation occurs in response to blocked DNA replication and certain forms of genotoxic stress (2). While phosphorylation at Ser345 serves to localize Chk1 to the nucleus following checkpoint activation (3), phosphorylation at Ser317 along with site-specific phosphorylation of PTEN allows for re-entry into the cell cycle following stalled DNA replication (4). Chk1 exerts its checkpoint mechanism on the cell cycle, in part, by regulating the cdc25 family of phosphatases. Chk1 phosphorylation of cdc25A targets it for proteolysis and inhibits its activity through 14-3-3 binding (5). Activated Chk1 can inactivate cdc25C via phosphorylation at Ser216, blocking the activation of cdc2 and transition into mitosis (6). Centrosomal Chk1 has been shown to phosphorylate cdc25B and inhibit its activation of CDK1-cyclin B1, thereby abrogating mitotic spindle formation and chromatin condensation (7). Furthermore, Chk1 plays a role in spindle checkpoint function through regulation of aurora B and BubR1 (8). Research studies have implicated Chk1 as a drug target for cancer therapy as its inhibition leads to cell death in many cancer cell lines (9).

1.  Liu, Q. et al. (2000) Genes Dev 14, 1448-59.

2.  Zhao, H. and Piwnica-Worms, H. (2001) Mol Cell Biol 21, 4129-39.

3.  Jiang, K. et al. (2003) J Biol Chem 278, 25207-17.

4.  Martin, S.A. and Ouchi, T. (2008) Mol Cancer Ther 7, 2509-16.

5.  Chen, M.S. et al. (2003) Mol Cell Biol 23, 7488-97.

6.  Zeng, Y. et al. (1998) Nature 395, 507-10.

7.  Löffler, H. et al. (2006) Cell Cycle 5, 2543-7.

8.  Zachos, G. et al. (2007) Dev Cell 12, 247-60.

9.  Garber, K. (2005) J Natl Cancer Inst 97, 1026-8.

• Data sheet (97KB)
• MSDS PDF